Clinical Trial Update: Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Niraparib-bevacizumab-Dostarlimab vs Niraparib-bevacizumab to standard of care in recurrent ovarian cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Niraparib-bevacizumab
• Niraparib-bevacizumab-Dostarlimab

Snippet

Sponsor: Nordic Society of Gynaecological Oncology - Clinical Trials Unit | Conditions: Ovarian Cancer | Phase 3 | Status: WITHDRAWN